CHAMPIONS ONCOLOGY, INC. CSBR

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds.

At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs. We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients who enroll in clinical trials (late stage, pretreated and metastatic). This characteristic of our TumorBank is an important differentiator to other established PDX banks. We implant and expand these tumors in mice, which allows for future studies and additional characterization of the tumor. Additional analytical and pharmacology experimental platforms are also available to augment the information gained from studies performed.

Last close 4.72 2026-10-23
Market cap —
52-week range 4.59 - 8.31

Valuation FY2025 figures against the last close

P/S1.1x
P/E—
P/FCF—
EV/EBITDA252.2x
Dividend yield—
Diluted EPS-0.08

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $59.4M$56.9M$50.2M$53.9M$49.1M$41.0M$32.1M$27.1M$20.2M$15.4M
Cost of revenue $30.9M$28.4M$29.4M$29.5M$23.6M$21.4M$17.0M———
Gross profit $28.5M$28.6M$20.8M$24.3M$25.5M$19.6M$15.1M———
R&D $9.1M$6.8M$9.5M$11.5M$9.4M$7.2M$5.9M$4.8M$4.4M$4.3M
SG&A $11.2M$9.3M$11.1M$10.2M$9.1M$6.5M$6.6M$4.7M$4.1M$5.0M
Total operating expenses ——————$33.9M$26.8M$21.6M$22.2M
Operating income -$1.1M$4.6M-$7.4M-$5.3M$607.0K$366.0K-$1.9M$270.0K-$1.4M-$6.8M
Pre-tax income -$929.0K$4.6M-$7.3M-$5.3M$583.0K$437.0K-$2.0M$231.0K-$1.4M-$6.9M
Income tax $246.0K$75.0K$32.0K$68.0K$35.0K$75.0K$130.0K$103.0K$33.0K$19.0K
Net income -$1.2K$4.7K-$7.3K-$5.3M$548.0K$362.0K-$2.1M$128.0K-$1.5M-$6.9M
EPS, basic -0.080.34-0.54-0.390.040.03-0.180.01-0.13—
EPS, diluted -0.080.33-0.54-0.390.040.02-0.180.01-0.13-0.64
Shares, diluted (wtd. avg.) 13.8M14.3M13.5M13.5M14.2M14.6M11.8M14.1M11.0M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $4.9M$9.8M$2.6M$10.1M$9.0M$4.7M$8.3M$3.2M$1.0M$3.4M
Receivables $13.2M$11.2M$9.5M$8.0M$9.5M$7.0M$4.8M$4.4M$3.9M$2.3M
Total current assets $19.2M$22.4M$13.6M$19.5M$19.7M$12.6M$13.5M$7.9M$5.1M$5.9M
Property, plant and equipment —————$6.1M$4.0M$2.5M$2.1M$1.2M
Goodwill $335.0K$335.0K$335.0K$335.0K$335.0K$335.0K$335.0K$669.0K$669.0K$669.0K
Total assets $27.0M$32.3M$26.1M$34.3M$35.4M$27.6M$20.8M$11.3M$8.1M$8.0M
Accounts payable $6.9M$4.2M$5.8M$5.3M$2.9M$1.9M$3.1M$2.8M$2.2M$1.9M
Total current liabilities $19.9M$23.9M$21.5M$21.7M$17.5M$11.2M$12.3M$8.0M$7.5M$7.4M
Total liabilities $22.9M$28.6M$28.0M$29.7M$26.3M$20.2M$15.7M$9.0M$8.1M$7.6M
Retained earnings -$81.1M-$79.9M-$84.6M-$77.3M-$72.0M-$72.5M-$72.9M-$70.7M-$70.8M-$69.3M
Total equity $3.9M$3.8M-$1.9M$4.6M$9.1M$7.4M$5.1M$2.1M$3.0K$400.0K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$4.5M$7.4M-$6.1M$4.0M$6.5M-$1.7M$2.9M$1.9M-$1.2M-$2.8M
Depreciation and amortisation $1.4M$1.6M$1.9M$2.1M$1.5M$925.0K$825.0K$606.0K$360.0K$168.0K
Stock-based compensation $1.2M$654.0K$1.1M$864.0K$912.0K$598.0K$600.0K$636.0K$1.0M$2.7M
Capital expenditure $564.0K$389.0K$836.0K$2.9M$2.4M$3.3M$2.2M$834.0K$1.2M$766.0K
Investing cash flow -$540.0K-$389.0K-$836.0K-$2.9M-$2.4M-$3.2M-$2.2M-$834.0K-$1.2M-$766.0K
Financing cash flow $99.0K$170.0K-$527.0K$11.0K$207.0K$1.2M$4.4M$1.2M$13.0K$4.3M
Buybacks —$0$634.0K$74.0K$0—————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-059373.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -20M 0 20M 40M 60M Revenue, FY2016: 15.4M Net income, FY2016: -6.9M Revenue, FY2017: 20.2M Net income, FY2017: -1.5M Revenue, FY2018: 27.1M Net income, FY2018: 128K Revenue, FY2019: 32.1M Gross profit, FY2019: 15.1M Net income, FY2019: -2.1M Revenue, FY2020: 41M Gross profit, FY2020: 19.6M Net income, FY2020: 362K Revenue, FY2021: 49.1M Gross profit, FY2021: 25.5M Net income, FY2021: 548K Revenue, FY2022: 53.9M Gross profit, FY2022: 24.3M Net income, FY2022: -5.3M Revenue, FY2023: 50.2M Gross profit, FY2023: 20.8M Net income, FY2023: -7.3K Revenue, FY2024: 56.9M Gross profit, FY2024: 28.6M Net income, FY2024: 4.7K Revenue, FY2025: 59.4M Gross profit, FY2025: 28.5M Net income, FY2025: -1.2K FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $15.4M $20.2M $27.1M $32.1M $41.0M $49.1M $53.9M $50.2M $56.9M $59.4M
Gross profit — — — $15.1M $19.6M $25.5M $24.3M $20.8M $28.6M $28.5M
Net income -$6.9M -$1.5M $128.0K -$2.1M $362.0K $548.0K -$5.3M -$7.3K $4.7K -$1.2K

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Shareholder vote Item 5.07

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%